Immunotherapy, a transformative approach in the field of oncology, harnesses the power of the body's immune system to combat cancer. This article aims to provide a comprehensive guide on this revolutionary treatment modality.
Immunotherapy, also known as biotherapy, involves the use of treatments that stimulate or restore the body's innate ability to fight cancer. It can be classified into several types: checkpoint inhibitors, CAR-T cell therapy, monoclonal antibodies, treatment vaccines, and immune system modulators.
Checkpoint inhibitors work by disrupting the signals that allow cancer cells to hide from the immune system. Notable examples include pembrolizumab and nivolumab. CAR-T cell therapy, on the other hand, involves the genetic modification of a patient's T cells to make them more effective at targeting cancer cells.
Monoclonal antibodies are lab-created molecules designed to mimic the immune system's ability to fight off harmful pathogens. They can be engineered to attack specific parts of cancer cells. Treatment vaccines, conversely, are designed to boost the immune system's response to cancers already present in the body.
Immune system modulators enhance the body's immune response against cancer. They include cytokines - proteins that facilitate communication between cells - and adjuvants that boost the immune response to an antigen.
Despite its promise, immunotherapy is not without challenges. These include managing immune-related adverse events and identifying biomarkers to predict response. Future research directions involve exploring combination therapies and developing novel immunotherapeutic strategies.
Immunotherapy represents a paradigm shift in cancer treatment, offering a promising alternative to traditional therapies. As our understanding of the immune system and cancer biology deepens, the potential for more effective and personalized immunotherapies continues to grow.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation